neurocoach.
My Care Plan
Explore optionsMedications

MEDICATIONS

Ibogaine research and serious safety risks

Experimental psychedelic drug under early-phase trial planning for PTSD and opioid use disorder; not FDA approved and associated with dangerous heart-rhythm risks.

NeuroCoach · Evidence explorerSources checked 2026-10-11Editorial draft · clinical review pending

How it works

Ibogaine is a psychoactive compound being investigated for selected psychiatric and substance-use conditions. FDA's October 2026 request for information concerns how early-phase studies might be conducted safely, not a finding that the drug works.

What the evidence says, use by use

Evidence is specific to the condition, population and—for devices—the exact product. One label never covers everything.

PTSD & Trauma: Investigational PTSD treatment

Experimental
Who was studied / who it’s for: Adults in potential tightly monitored early-phase studiesRegulatory status: No FDA-approved ibogaine treatment for PTSD. FDA invited clinical-trial design comments through November 20, 2026 under docket FDA-2026-N-10429.What this label means: Not established for routine use for this purpose. May be theoretical or in very early research.

HHS is prioritizing initial federally supported research in adults with PTSD and opioid use disorder. FDA is seeking evidence on eligibility, study design and extensive cardiac and neurological safety monitoring. No clinical efficacy conclusion or routine-care recommendation follows from the RFI.

Sources: FDA (October 5, 2026) · Federal Register (October 6, 2026)

Who usually provides it

Legitimate investigator-supervised trials only; no home or commercial dosing instructions are appropriate.

Cautions & things to know

  • Serious QTc prolongation can cause life-threatening arrhythmias and death. Neurologic risks, seizures and interactions with many psychiatric medications are important concerns.
  • The FDA describes potential inpatient monitoring and resuscitation capability for contemplated trials. These are proposed safeguards, not a guide to self-treatment.
  • Special caution is warranted with psychosis, bipolar conditions and other complex medication regimens. Do not stop any prescribed medicines to pursue ibogaine.
  • An FDA request for public information is NOT marketing approval, endorsement or evidence of effectiveness.

Questions for a clinician

Conversation prompts, not a treatment plan.

  • Is this intervention authorized for the condition, or only being studied?
  • What benefits and harms have been established by controlled human trials?
  • What approved PTSD or substance-use treatments should we consider with a clinician first?

Educational, not medical advice. NeuroCoach is an educational and care-navigation resource, not a medical provider. Information about medications, supplements, therapies, devices, clinical trials and community experiences is provided for education and exploration and is not a recommendation, diagnosis or treatment plan. Evidence varies substantially among interventions. Decisions about medical or mental-health treatment should be made with an appropriately qualified healthcare professional. Do not start, stop or change medication, supplements or treatment based solely on information found here.

Sources

Sources checked 2026-10-11. Educational editorial draft; clinical review pending.

  1. Request for information on early-phase ibogaine trial design FDA (October 5, 2026)
  2. Design and safety considerations for ibogaine drug trials, Docket FDA-2026-N-10429 Federal Register (October 6, 2026)